SHMT2 and kidney cancer: Combined with the above outcomes, we could suppose that SHMT2 and its co-expressed gene NDUFA4L2 may modulate the initiation and development of kidney cancer and influence its prognosis, which may serve as the potential targets for kidney cancer treatment.